A 33-year-old male with schizophrenia has been hospitalized three times in the past year, each time after stopping his oral risperidone due to poor insight into his illness. He responds well to antipsychotic treatment during hospitalizations but consistently discontinues oral medication within weeks of discharge. The PMHNP discusses transitioning to a long-acting injectable (LAI) antipsychotic. Which of the following best describes the primary clinical advantage of LAI formulations in this patient?